This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC3B0CQ_M.jpg
The unit could fetch about $3.5 billion in sale, according to the report.
The pharma business was expected to garner interest from IFF’s peers and private equity firms, Bloomberg reported.
IFF’s pharma unit accounted for about 8% of the company’s total sales last year.
IFF did not immediately respond to a Reuters request for comment.
